publication date: Aug. 7, 2015
Conversation with The Cancer Letter
AstraZeneca Exec Discusses Iressa’s Future in the U.S.
After a decade of near-absence from the U.S. market, the AstraZeneca drug Iressa (gefitinib) is back.
The drug, which stayed on the market between 2003 and 2005, when it was pulled because clinical trials in a general population of patients failed to demonstrate a survival advantage, has returned. Now it is accompanied by a diagnostic tests that selects patients.
The Cancer Letter asked Andrew Coop, vice president of US medical affairs in oncology at AstraZeneca, to discuss the company’s plans for the future of Iressa in the US, and lessons that have been learned.
Report: Part D Drug Prices “Needlessly High”
Medicare’s Part D program paid significantly higher prices for drugs than either Medicaid or the Veterans Health Administration, a study by Carleton University and Public Citizen found.
Prices paid by Medicare Part D were also above those in 30 other countries.
The price is caused by congressional restrictions on the federal government’s ability to negotiate with the pharmaceutical industry, the study said.
Carolyn Kaelin, 54, Dana-Farber Surgical Oncologist and Researcher
Carolyn Mary Kaelin, a surgical oncologist in the Women’s Cancers Program at Dana-Farber and director of the Breast Clinic at Brigham and Women’s Hospital, died July 28, surrounded by loved ones. Kaelin was 54.
Lehigh Valley Health Network joins MSK Cancer Alliance
- Siteman Cancer Center receives “exceptional” rating from NCI
John Cunningham named chairman of pediatrics department at the University of Chicago
- Jinhgui Zhang named first chair of Department of Computational Biology at St. Jude
Stephen Lessnick named director of childhood cancer center at Research Institute at Nationwide Children’s Hospital
GI Chair Lopa Mishra to leave MD Anderson Cancer Center
Leukemia & Lymphoma Society receives donation from Bristol Myers Squibb
Commission on Cancer names Outstanding Achievement Award winners
California Dept. of Public Health launches big data collaboration with St. Joseph’s Health
Pan-Mass Challenge raises $33.5 million over weekend bike ride for Dana-Farber
| ||Drugs and Targets|
The Cancer Letter will be taking a short publication break, and will return Friday, Sept. 4.